Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intravenous Infusions's change in working capital for the quarter that ended in . 20 was GHS0.00 Mil.
Intravenous Infusions's change in working capital for the fiscal year that ended in . 20 was GHS0.00 Mil.
It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).
Intravenous Infusions Change In Working Capital Related Terms
Intravenous Infusions Change In Working Capital Historical Data
* Premium members only.
The historical data trend for Intravenous Infusions's Change In Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions Change In Working Capital Chart
Intravenous Infusions Change In Working Capital Calculation
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Working Capital for the trailing twelve months (TTM) ended in . 20 was GHS0.00 Mil.
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.
Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net
(566)
(614)
(796)
Inventories
(1,667)
(2,759)
(3,727)
Accounts payable
531
1,061
2,687
Accrued liabilities
103
271
(935)
Accrued income taxes
(1,224)
981
994
For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Working Capital of GHS0.00 Mil mean?
Intravenous Infusions (XGHA:IIL) has a Change In Working Capital of GHS0.00 Mil as of . 20. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Intravenous Infusions.
Is Intravenous Infusions' Change In Working Capital too high?
Intravenous Infusions' current Change In Working Capital is GHS0.00 Mil. Overall, Intravenous Infusions has a GF Score™ of 3/100, reflecting its overall financial health beyond just this single metric.
How does Intravenous Infusions' Change In Working Capital compare to PTLF and PCYN?
Intravenous Infusions' Change In Working Capital of GHS0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Working Capital for a Drug Manufacturers company?
A good Change In Working Capital depends on the Drug Manufacturers industry context. However, Change In Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Working Capital mean?
A high Change In Working Capital can signal that a stock is expensive relative to its fundamentals. Change in Working Capital is the difference between current assets less current liabilities between the current period and the past period. View historical data for Intravenous Infusions. Intravenous Infusions's current Change In Working Capital is GHS0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Change In Working Capital of GHS0.00 Mil. The current Change In Working Capital is GHS0.00 Mil. Intravenous Infusions' overall GF Score™ is 3/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Working Capital calculated?
Change In Working Capital is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Change In Working Capital is GHS0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.
3GF Score
Get the complete analysis for XGHA:IIL
Change In Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XGHA:IIL has been successfully added to your 
